Compare ATAI & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATAI | ANGO |
|---|---|---|
| Founded | 2018 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 439.8M |
| IPO Year | 2021 | 2004 |
| Metric | ATAI | ANGO |
|---|---|---|
| Price | $3.34 | $10.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $15.57 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 4.6M | 266.6K |
| Earning Date | 03-06-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.92 |
| EPS | N/A | ★ N/A |
| Revenue | $308,000.00 | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.11 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $1.15 | $8.36 |
| 52 Week High | $6.73 | $13.99 |
| Indicator | ATAI | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 50.24 |
| Support Level | $3.06 | $10.38 |
| Resistance Level | $4.30 | $11.06 |
| Average True Range (ATR) | 0.21 | 0.39 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 6.09 | 50.00 |
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.